title: Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis.
abstract: Much is known about specific antibodies and their titers in patients with tuberculosis. However, little is known about the avidity of these antibodies or whether changes in avidity occur during the progression of the disease or during treatment. The aims of this study were to determine the avidity of antibodies to Mycobacterium tuberculosis in patients with pulmonary tuberculosis, to explore the value of avidity determination for the diagnosis of tuberculosis, and to study changes in levels of antibodies and their avidity during treatment. Antibody avidity was measured by an enzyme-linked immunosorbent assay with thiocyanate elution. Avidity indices and serum levels of immunoglobulin G to M. tuberculosis were determined for 22 patients with pulmonary tuberculosis before and during treatment and for 24 patients with other pulmonary diseases. Antibody levels and avidity were both significantly higher in untreated tuberculosis patients than in the controls. Avidity determination had more diagnostic potential than determination of the antibody levels. Tuberculosis patients with a long duration of symptoms had higher antibody avidity than those with a recent onset of symptoms, indicating affinity maturation of specific antibodies during active disease. In the early phase of treatment, a decrease in antibody avidity was observed for 73% of all tuberculosis patients, accompanied by an initial increase in antibody levels in 36% of these patients. These phenomena could be explained by an intense stimulation of the humoral response by antigens released from killed bacteria, reflecting early bactericidal activity of antituberculous drugs leading to the production of low-affinity antibodies against these released antigens.
authors.affiliation: Koninklijk Instituut voor de Tropen/Royal Tropical Institute Biomedical Research and Division of Pulmonary Diseases, Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: Lenka M Pereira
authors.initials: LM
authors.lastname: Arias-Bouda
authors.forename: Sjoukje
authors.initials: S
authors.lastname: Kuijper
authors.forename: Anouk
authors.initials: A
authors.lastname: Van der Werf
authors.forename: Lan N
authors.initials: LN
authors.lastname: Nguyen
authors.forename: Henk M
authors.initials: HM
authors.lastname: Jansen
authors.forename: Arend H J
authors.initials: AH
authors.lastname: Kolk
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D000915:Antibody Affinity; D000995:Antitubercular Agents / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D008171:Lung Diseases / Q000276:immunology; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000995:Antitubercular Agents; D007074:Immunoglobulin G